Companies · ALNY
Alnylam Pharmaceuticals
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Jul 30, 2026
Alnylam cuts FY2026 TTR revenue guidance by $200M at midpoint as ATTR-CM second-line demand normalizes post-pent-up launch surge
Alnylam's Q2 2026 results reveal a structural deceleration in ATTR-CM second-line demand that management now characterizes as normalization after pent-up demand exhaustion, forcing a $200 million midpoint reduction in full-year TTR guidance to $4,200–$4,500 million. AMVUTTRA posted $1.01 billion in Q2 net product revenue, up 106% year-over-year, and the company turned GAAP profitable for the quarter with net income of $164.5 million versus a loss of $72.2 million in Q2 2025. Pipeline breadth accelerated simultaneously — two new Phase 2 initiations (ALN-6400 in von Willebrand disease, mivelsiran in Down syndrome-associated Alzheimer's disease) and a strategic AI collaboration with Inceptive Nucleics signal continued investment in platform and pipeline despite the commercial reset.
Tone: mixedRevenue
$3.7B
ALNY 10-K · FY 2025
Employees
2,500
Revenue growth YoY
+65%
Founded
2002
Profile
ALNY 10-K Item 1 · Feb 12, 2026Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneers RNAi therapeutics — medicines that silence disease-causing genes before the harmful proteins are made. The company has six approved first-in-class products spanning rare and prevalent diseases, with a pipeline of more than 20 clinical programs. In early 2026 it launched the Alnylam 2030 strategy targeting 25%+ total revenue CAGR and approximately 30% non-GAAP operating margin by year-end 2030.
Read filing description ↓ Collapse description ↑
Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. By harnessing the RNAi pathway, we have pioneered a new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, that function upstream of conventional medicines by potently silencing messenger RNA, or mRNA, that encode for proteins implicated in the cause or pathway of disease, thus preventing them from being made. We believe this is a revolutionary approach with the potential to transform the care of patients across a broad range of disease areas and indications. To date, our efforts to advance this revolutionary approach have yielded the approval of six first-in-class RNAi-based medicines: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), Leqvio (inclisiran) and Qfitlia (fitusiran). Our research and development strategy is to target genetically validated genes that have been implicated in the cause or pathway of human disease. We utilize a N-acetylgalactosamine (GalNAc) conjugate approach or lipid nanoparticle (LNP) to enable hepatic delivery of siRNAs. For delivery to the central nervous system, or CNS, and the eye (ocular delivery), we are utilizing an alternative conjugate approach based on a hexadecyl (C16) moiety as a lipophilic ligand. We are also advancing approaches for heart, skeletal muscle and adipose tissue delivery of siRNAs. Our focus is on clinical indications where there is a high unmet need, a genetically validated target, early biomarkers for the assessment of clinical activity in Phase 1 clinical trials, and a definable path for drug development, regulatory approval, patient access and commercialization. We currently have six marketed products, including two products that are commercialized by collaborators, and more than 20 clinical programs, including several in late-stage development.
Primary products
- AMVUTTRA (vutrisiran)
- ONPATTRO (patisiran)
- GIVLAARI (givosiran)
- OXLUMO (lumasiran)
- Leqvio (inclisiran)
- Qfitlia (fitusiran)
Business segments
End markets
Geographies
Named customers
Named competitors
“Competition in the pharmaceutical marketplace remains intense, with hundreds of companies competing to discover, develop, and market new drugs.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenues grew 65% year-over-year in 2025, driven primarily by an 81% increase in net product revenues, itself dominated by a 138% surge in AMVUTTRA sales following FDA approval for ATTR-CM in March 2025.
The rest of ALNY is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.